戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mportant for cellular growth and survival of infantile hemangioma.
2 owth factor-D is a target of itraconazole in infantile hemangioma.
3 ram per day for 6 months in the treatment of infantile hemangioma.
4 clinical evaluation and treatment of CMN and infantile hemangioma.
5  guide future standard-of-care treatment for infantile hemangioma.
6 ng from systemic use of propranolol to treat infantile hemangioma.
7 lockers have been used to successfully treat infantile hemangioma.
8 c potential of stem cells derived from human infantile hemangioma.
9 ergic blocker that is first line therapy for infantile hemangioma.
10 -1 and merosin, immunodiagnostic markers for infantile hemangioma.
11 ar malformations, juvenile angiofibromas and infantile hemangiomas.
12  treatment of benign vascular tumors such as infantile hemangiomas.
13 romise for the treatment of certain types of infantile hemangiomas.
14 ine therapy for the treatment of complicated infantile hemangiomas.
15 fantile hemangiomas and treating complicated infantile hemangiomas.
16 sm of action of propranolol on regression of infantile hemangiomas.
17 nsible for the formation and rapid growth of infantile hemangiomas.
18 Objectives: To describe the sequelae left by infantile hemangiomas after natural involution and to id
19 opranolol has been used to treat complicated infantile hemangiomas, although data from randomized, co
20 tifies a stem cell as the cellular origin of infantile hemangioma and describes for what we believe i
21 s in a previously described in vivo model of infantile hemangioma and in cultured hemangioma-derived
22 stly, in a patient-derived in vitro model of infantile hemangioma and pre-clinical model of HLTRS we
23 clinical features, including the presence of infantile hemangioma and radiological features based on
24 es of these lesions are shared with those of infantile hemangioma and tufted angioma of children, but
25 is and psoriasis, use of topical timolol for infantile hemangiomas and bone marrow transplantation fo
26 e treatment of atopic dermatitis, psoriasis, infantile hemangiomas and dystrophic epidermolysis bullo
27 treatments for atopic dermatitis, psoriasis, infantile hemangiomas and dystrophic epidermolysis bullo
28 escribing clinical syndromes associated with infantile hemangiomas and treating complicated infantile
29  as wet age-related macular degeneration and infantile hemangioma are more common in light-skinned in
30 hat the transcriptomes of human placenta and infantile hemangioma are sufficiently similar to suggest
31                                              Infantile hemangiomas are benign tumors of vascular endo
32                                              Infantile hemangiomas are characterized by rapid capilla
33        Congenital melanocytic nevi (CMN) and infantile hemangiomas are commonly encountered in newbor
34                                              Infantile hemangiomas are composed of endothelial cells
35                                              Infantile hemangiomas are endothelial tumors that grow r
36                                              Infantile hemangiomas are localized and rapidly growing
37                                           As infantile hemangiomas are reported to express high level
38                                              Infantile hemangiomas are the most common benign tumors
39   Corticosteroids are commonly used to treat infantile hemangioma, but the mechanism of action of thi
40 ccurred in redefining the clinical course of infantile hemangiomas, describing clinical syndromes ass
41    Little is known about the pathogenesis of infantile hemangiomas despite the fact that they are rel
42                        Although most CMN and infantile hemangiomas do not require active intervention
43 fungal agent, can clinically improve or cure infantile hemangioma; however, the underlying molecular
44 (3 mg/kg/day) in the treatment of periocular infantile hemangioma (IH) based on clinical and radiolog
45                                              Infantile hemangioma (IH) is a benign vascular tumor tha
46                                              Infantile hemangioma (IH) is a common childhood vascular
47                                              Infantile hemangioma (IH) is the most common tumor of in
48                        Recognizing segmental infantile hemangioma (IH) patterns is important for risk
49                                 Treatment of infantile hemangioma (IH) with topical timolol in the fi
50  atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-)
51                              Herein, we used infantile hemangioma (IH), the most common tumor of infa
52 (HemSCs) are multipotent cells isolated from infantile hemangioma (IH), which form hemangioma-like le
53       Ulceration is a common complication of infantile hemangioma (IH), which leads to substantial mo
54                                              Infantile hemangiomas (IH) are common tumors for which t
55                              Propranolol for infantile hemangiomas (IH) has been shown to be effectiv
56                      Propranolol therapy for infantile hemangiomas (IH) is now being used widely, and
57 gonist, is the first-line therapy for severe infantile hemangiomas (IH).
58                                              Infantile hemangiomas (IHs) are common benign tumors of
59                                              Infantile hemangiomas (IHs) are the most common benign t
60 ) syndrome to be 31% in children with facial infantile hemangiomas (IHs) of at least 22 cm2.
61 actice guidelines exist for the treatment of infantile hemangiomas (IHs), recommendations are heterog
62 nign vascular tumors that differ from common infantile hemangiomas in that they grow in utero and are
63                  Conventional treatments for infantile hemangioma include the use of corticosteroids,
64                                  Importance: Infantile hemangiomas involute to some extent, but they
65                                              Infantile hemangioma is a benign endothelial tumor compo
66                                              Infantile hemangioma is a common vascular tumor with a u
67                                              Infantile hemangioma is an endothelial tumor that grows
68                                              Infantile hemangioma is the most common benign vascular
69 f the pathogenic endothelial cells in common infantile hemangioma is unknown.
70 evolutionized the treatment of proliferating infantile hemangiomas, laser and/or surgical excision ar
71 common, predominantly benign complication in infantile hemangioma, little is known about the prognosi
72 gests that the unique self-limited growth of infantile hemangioma may, in fact, mirror the lifetime o
73 e pathogenic C482R VEGFR-2 mutant, linked to infantile hemangioma, promotes ligand-independent signal
74 220 parents/caregivers completed the 35-item Infantile Hemangioma Quality-of-Life (IH-QoL) instrument
75 hat EndMT induced by M1 macrophages promotes infantile hemangioma regression and may lead to novel th
76 ants 1 to 5 months of age with proliferating infantile hemangioma requiring systemic therapy.
77                           Human placenta and infantile hemangioma samples highly express ECSCR protei
78 etrospective cohort study of images from 187 infantile hemangiomas that had not received systemic tre
79                              Most are benign infantile hemangiomas that typically regress by 5 years
80 he ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy
81  cells recapitulated the unique evolution of infantile hemangioma--the formation of blood vessels fol
82 udies have shown a promising new therapy for infantile hemangioma using nonselective beta-blockers, i